Can Molecular Simulation Platforms Become the "Digital Microscope" for Biomolecular R&D?

In the frontier fields of synthetic biology, drug discovery, and protein engineering, researchers have long faced a core technological bottleneck: biomolecules possess inherent dynamic, flexible, and motile properties. While mainstream experimental approaches such as X-ray crystallography and cryo-electron microscopy primarily provide high-resolution static structures—and can obtain partial dynamic information through techniques like time-resolved and multi-conformational analysis—they cannot systematically capture the complete dynamic behavior of molecules in real physiological environments across timescales from picoseconds to seconds, nor the energy-driven mechanisms of molecular interactions. The emergence of molecular simulation platforms has effectively addressed this challenge. As a digital R&D infrastructure, it enables researchers to accurately observe molecular dynamics in virtual environments, decipher interaction mechanisms, and predict environmental responses, advancing biomolecular R&D from "experimental trial-and-error" to "computational prediction."

According to Bespoke Consulting statistics, the global molecular simulation market reached approximately RMB 5.823 billion in 2025 and is projected to grow to RMB 13.618 billion by 2032. As a core component of the broader biosimulation market, the rapid growth of molecular simulation is driven by the deep integration of AI technologies.

I. What Is a Molecular Simulation Platform? The Leap from Static Structure to Dynamic Evolution

Biomolecular Computing Tetrahedron.

Biomolecular Computing Tetrahedron

A molecular simulation platform is an integrated R&D platform that combines core algorithms, including molecular dynamics simulation, quantum chemical computation, free energy prediction, and virtual screening. Its core value lies in accurately constructing three-dimensional molecular models in silico, simulating molecular trajectories and interaction processes over time using classical physical laws and AI algorithms, and predicting their behavior and function in real-world environments.

Traditional molecular simulation has been heavily dependent on manual operations—manual modeling, input file writing, job submission, and data review—resulting in cumbersome workflows, high barriers to entry, and low efficiency. Next-generation AI-powered molecular simulation platforms have achieved three major upgrades:

First, full-process automation. The platform integrates modeling, parameter setting, simulation execution, and result analysis into standardized workflows. The MDriver platform, developed by a domestic research team, incorporates natural language interaction and automatic code generation, allowing researchers to complete full-process simulations simply by inputting simulation requirements.

Second, deep AI integration. Next-generation simulation technologies centered on machine learning force fields (MLFF) have effectively overcome the accuracy limitations of traditional empirical force fields. The MAPLE platform, published in Chemical Science in 2026 (developed by an international research team), leverages the UMA large-scale machine learning force field (trained on the Open Molecules 2025 dataset, covering 83 elements) to accurately support chemical reaction and open-shell system simulations.

Third, multi-scale integration. Next-generation platforms integrate quantum chemical computation, all-atom dynamics simulation, and coarse-grained simulation, enabling cross-scale unified modeling. Researchers can conduct full-chain studies from electronic structure to cellular signaling pathways within a single platform.

II. Core Technical Modules of Molecular Simulation Platforms

Language To Lab Closed Loop Workflow

Mature molecular simulation platforms build complete R&D capabilities around four core modules:

First, the Molecular Dynamics (MD) Simulation Engine. By solving Newton's equations of motion at the atomic scale, it simulates dynamic conformational changes of molecules across timescales from nanoseconds to microseconds or even milliseconds, serving as a core foundational tool for structural biology and drug discovery.

Second, Free Energy Calculation and Binding Affinity Prediction. Accurately quantifying intermolecular binding strength, this capability has been deeply integrated into automated workflows. Taking a multi-agent framework as an example, it can autonomously complete MD simulations of protein–ligand complex systems and compute binding free energies using the MM/PB(GB) SA method.

Third, Virtual Screening and Molecular Docking. Rapidly identifying high-activity molecules from massive compound libraries: Next-generation platforms integrate machine learning with traditional docking techniques to build intelligent screening workflows.

Fourth, AI-Driven Structure Prediction and Intelligent Design. AI structure prediction tools such as AlphaFold have become standard platform features. Next-generation platforms go further by simulating dynamic conformational changes of proteins in their functional states.

The MatwingsVenus™ （晓鹜™） platform, independently developed by Matwings, is a representative example in this direction. According to the Matwings official website, it is an agent-centric conversational protein R&D platform. Users propose functional requirements through natural language, AI completes sequence design, and the platform automatically connects to automated laboratories, directing robots to complete sample preparation, protein purification, and functional testing—achieving full-process intelligent R&D with a "conversational dry–wet closed loop." The platform supports retrieval from tens of billions of real labeled protein data points, integrates 200+ design tools, 50+ certified experts, and 30+ domain-specific Skills. According to Matwings' June 2026 disclosure, the platform added three core models—BoltzGen, LigandMPNN, and Protenix—to its "protein generation" module, continuously expanding the boundaries of molecular simulation and protein design capability.

III. Industrial Applications of Molecular Simulation Platforms

Unified Molecular Simulation Platform

Molecular simulation platforms have been fully deployed across core domains including drug R&D, industrial enzyme engineering, materials science, and antibody design.

In drug R&D, the global drug simulation platform market reached $3.146 billion in 2025 (QYResearch). Platforms established by domestic university key laboratories support full-process R&D including large-scale molecular generation, virtual screening, MD simulation, and quantum chemical computation.

The MatwingsVenus™ （晓鹜™） platform's application in innovative drug development has been validated through real-world projects. According to official disclosures, in a de novo design project targeting an immune-regulatory receptor, the platform successfully obtained dozens of novel binder molecules with in vitro cell-blocking activity. The target was novel, lacking comparable references, with a surface dominated by polar regions and a natural ligand possessing nM-level affinity—making the design extremely challenging. Leveraging the platform, the agent automatically completed scaffold screening, interface design, sequence optimization, and druggability prediction. Samples prepared through automated experimentation performed exceptionally well in in vitro assays, with dozens of molecules demonstrating clear cell-blocking activity.

In industrial enzyme engineering, the MatwingsVenus™ （晓鹜™） platform supports two core functions—"AI-directed evolution" and "AI enzyme mining"—breaking through the traditional "sequence–structure–function" prediction paradigm to achieve self-closed-loop design from functional requirements to original sequences, providing a new pathway for rapid enzyme iteration.

In materials science, molecular simulation is extending into advanced materials fields such as battery materials design, with industry-leading platforms deploying property simulation workflows including solution viscosity thin-layer shear simulation.

In antibody drug design, a domestic research team developed the Void-X atomic interaction generation model (PNAS 2026), which employs a "bottom-up" physics-driven design paradigm, providing a physically interpretable core solution for precise protein interface design.

IV. Molecular Simulation Platforms Enter the AI-Native Era

The molecular simulation industry is transitioning from "computational assistive tools" to "AI-native operating systems," with three major trends reshaping the industry landscape:

Trend 1: AI force fields replacing traditional force fields. Machine learning force fields represented by UMA cover 83 elements, enabling accurate simulation of chemical reactions and open-shell systems, upgrading molecular simulation from "empirical estimation" to "atomic-level high-precision prediction."

Trend 2: Natural language-driven "zero-code" simulation. Platforms such as CFDriver/MDriver have achieved natural language-driven automated simulation. MatwingsVenus™ （晓鹜™） similarly embodies this concept—researchers describe requirements through natural language, and the agent completes the entire process from research to sequence generation to functional design, while connecting to cloud-based automated laboratories for preparation and testing, advancing protein R&D from "large-platform driven" to "accessible to individuals."

Trend 3: Deep dry–wet closed-loop integration. After AI completes molecular design, it connects to automated experimental equipment, with experimental data flowing back in real time to drive model iteration, forming a positive closed loop of "computational design → experimental validation → data feedback → model upgrading." According to Matwings' official website, the MatwingsVenus™ platform can route design results to plasmid ordering and experimental scheduling workflows through its proprietary communication mechanisms, directing robots to complete sample preparation and functional testing. Experimental results flow back to the next round of AI design, forming a "conversational dry–wet closed loop" iteration. Sequences can be imported to the wet-lab ordering page with a single click, enabling seamless integration from design to experiment.

V. Conclusion

Molecular simulation platforms are restructuring the underlying logic of biomolecular R&D, advancing the industry from the empirical trial-and-error paradigm of "synthesize first, test later" to the data-driven paradigm of "simulate first, validate later." They enable researchers to preview molecular dynamics, predict engineering outcomes, and verify drug activity in virtual environments—significantly compressing timelines, reducing costs, and unleashing productivity.

From the MAPLE platform to MatwingsVenus™ （晓鹜™）, cutting-edge technological breakthroughs corroborate a single trend: molecular simulation platforms have become the core "operating system" of the bioeconomy, building a predictable, programmable, and iterative digital foundation for the complex, dynamic molecular world—an essential infrastructure supporting synthetic biology, innovative drug discovery, and the high-quality development of green biomanufacturing. Just as CAD reshaped engineering design and EDA restructured the chip industry, molecular simulation platforms are profoundly transforming the underlying logic of biomolecular R&D and driving the large-scale, intelligent development of the global bioeconomy.